Tamoxifen (antioestrogen) and aromatase inhibition (oestrogen deprivation) are distinct approaches to oestrogen-dependent breast cancer and efficacy, tolerability and toxicity differences stem from these pharmacological fundamentals (Smith and Dowsett, 2003). Here, CYP19A1 is linked to breast cancer.